BR112018003212A2 - diacerein or analogues thereof to inhibit asc expression, nlrp3 expression and / or inflammasome nlrp3 complex formation - Google Patents

diacerein or analogues thereof to inhibit asc expression, nlrp3 expression and / or inflammasome nlrp3 complex formation

Info

Publication number
BR112018003212A2
BR112018003212A2 BR112018003212-3A BR112018003212A BR112018003212A2 BR 112018003212 A2 BR112018003212 A2 BR 112018003212A2 BR 112018003212 A BR112018003212 A BR 112018003212A BR 112018003212 A2 BR112018003212 A2 BR 112018003212A2
Authority
BR
Brazil
Prior art keywords
disease
fibrosis
subject
nlrp3
chronic
Prior art date
Application number
BR112018003212-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Chen Chih-Kuang
Lee Jing-Yi
Lu Wei-Shu
Oscar Brown Carl Iii
Original Assignee
Twi Biotechnology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology, Inc. filed Critical Twi Biotechnology, Inc.
Publication of BR112018003212A2 publication Critical patent/BR112018003212A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
BR112018003212-3A 2015-08-17 2016-08-17 diacerein or analogues thereof to inhibit asc expression, nlrp3 expression and / or inflammasome nlrp3 complex formation BR112018003212A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206102P 2015-08-17 2015-08-17
US62/206,102 2015-08-17
PCT/US2016/047272 WO2017031161A1 (en) 2015-08-17 2016-08-17 Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex

Publications (1)

Publication Number Publication Date
BR112018003212A2 true BR112018003212A2 (en) 2018-09-25

Family

ID=58051269

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003212-3A BR112018003212A2 (en) 2015-08-17 2016-08-17 diacerein or analogues thereof to inhibit asc expression, nlrp3 expression and / or inflammasome nlrp3 complex formation

Country Status (13)

Country Link
US (1) US10195170B2 (https=)
EP (2) EP4147694A1 (https=)
JP (3) JP6887987B2 (https=)
KR (1) KR20180037261A (https=)
CN (1) CN108349867B (https=)
AU (2) AU2016308121A1 (https=)
BR (1) BR112018003212A2 (https=)
CA (1) CA2994987C (https=)
IL (1) IL257379A (https=)
MX (1) MX2018002049A (https=)
RU (1) RU2729066C2 (https=)
TW (1) TWI743047B (https=)
WO (1) WO2017031161A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
RU2019123160A (ru) 2016-12-29 2021-01-29 Юниверсити Оф Майами Способ модуляции активности инфламмасом и воспаления в легком
CN110177547B (zh) 2017-01-18 2022-09-27 台睿生物科技股份有限公司 用于治疗炎症性肠病和肠结肠炎的组合物
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
WO2019032672A1 (en) * 2017-08-11 2019-02-14 Olatec Therapeutics Llc METHOD OF TREATING SCHNITZLER SYNDROME
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
SG11202013176VA (en) 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions
KR102075724B1 (ko) * 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도
IL283127B1 (en) * 2018-11-14 2026-02-01 Smilebiotek Zhuhai Ltd Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders
CN113226309B (zh) * 2018-12-03 2024-10-29 珠海岐微生物科技有限公司 一种治疗年龄相关性黄斑变性的方法
CN120208846A (zh) 2019-01-14 2025-06-27 载度思生命科学有限公司 经取代的磺酰脲类衍生物
CN109833292A (zh) * 2019-02-23 2019-06-04 河南省人民医院 一种双醋瑞因滴眼液及其用途
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN110179865A (zh) * 2019-06-26 2019-08-30 广州中医药大学(广州中医药研究院) 一种大黄蒽醌类成分的制备方法及其应用
CN110787157A (zh) * 2019-11-27 2020-02-14 中南民族大学 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
US20230070129A1 (en) * 2020-01-06 2023-03-09 Seasun Therapeutics Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient
CN111358950A (zh) * 2020-03-20 2020-07-03 厦门大学 Caspase-1及ASC/Caspase-8作为靶点的应用
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
CN115616216B (zh) * 2021-07-15 2025-08-12 华南理工大学 抑制或阻断faah与nlrp3之间相互作用的制剂的用途
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128317A1 (en) * 2001-01-23 2002-09-12 Laboratories Negma Treatment of pathological conditions characterized by an increased IL-1 level
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
GB0404953D0 (en) * 2004-03-04 2004-04-07 Arakis Ltd Pro-drugs
WO2010003092A1 (en) 2008-07-03 2010-01-07 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
CN102060809B (zh) * 2009-05-01 2015-05-20 常州高新技术产业开发区三维工业技术研究所有限公司 一种大黄酸衍生物及其制备和用途
KR101567925B1 (ko) 2010-04-08 2015-11-10 티더블유아이 바이오테크놀로지 인코포레이티드 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법
EP2598536A1 (en) * 2010-07-29 2013-06-05 Université de Genève Process for the esterification of hyaluronic acid with hydrophobic organic compounds
CN103429236B (zh) * 2011-03-11 2016-09-21 安成生物科技股份有限公司 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物
US9707272B2 (en) 2011-07-12 2017-07-18 Universitat Zurich Method for the treatment of acne by administering IL-1β antibody
US8652540B2 (en) * 2012-06-04 2014-02-18 Hong Kong Baptist University Method of using rhein for treating fibrotic conditions and tumors
CN103110617A (zh) * 2013-03-22 2013-05-22 中国人民解放军肾脏病研究所 一种双醋瑞因在制备治疗糖尿病肾病药物中的用途
KR101486147B1 (ko) * 2013-07-09 2015-01-23 주식회사 엘지생활건강 Tslp 분비 저해능 및 이에 의한 알러지성 질환의 개선능을 가지는 조성물
MX373702B (es) * 2015-07-01 2020-05-07 Twi Biotechnology Inc Formulaciones topicas de diacereina o rheina y sus usos.

Also Published As

Publication number Publication date
TW201717927A (zh) 2017-06-01
CN108349867A (zh) 2018-07-31
JP2018523687A (ja) 2018-08-23
AU2021200117A1 (en) 2021-03-18
RU2018109237A3 (https=) 2019-12-31
RU2729066C2 (ru) 2020-08-04
IL257379A (en) 2018-04-30
HK1254388A1 (zh) 2019-07-19
TWI743047B (zh) 2021-10-21
US10195170B2 (en) 2019-02-05
US20170049733A1 (en) 2017-02-23
JP2023078360A (ja) 2023-06-06
EP3337782A4 (en) 2019-04-03
EP3337782A1 (en) 2018-06-27
RU2018109237A (ru) 2019-09-19
WO2017031161A1 (en) 2017-02-23
CA2994987C (en) 2023-09-26
KR20180037261A (ko) 2018-04-11
MX2018002049A (es) 2018-06-15
AU2021200117B2 (en) 2023-09-28
AU2016308121A1 (en) 2018-03-01
CA2994987A1 (en) 2017-02-23
JP2021121605A (ja) 2021-08-26
JP6887987B2 (ja) 2021-06-16
EP4147694A1 (en) 2023-03-15
CN108349867B (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
AU2021200117B2 (en) Diacerein or its analogs for inhibiting expression of ASC, NLRP3, and/or formation of NLRP3 inflammasome complex
JP2017512757A (ja) 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法
US20110262449A1 (en) Method for the treatment of gout or pseudogout
US20070190043A1 (en) Use of a topical medicament comprising riluzole
JP2018177788A (ja) Ｎｔｃｐ阻害剤によるアテローム性動脈硬化、原発性胆汁性肝硬変およびｎｒｌｐ３インフラマソーム関連疾患の治療
RS61053B1 (sr) Pоstupak za sprečavanje i / ili lečenje kognitivnog oštećenja povezanog sa starenjem i neuroinflamacijom
KR20170140383A (ko) 펩티드 조성물 및 사용 방법
US20250367229A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
KR20210105916A (ko) 우루소데옥시콜산을 함유하는 노시의 치료 또는 예방제
AU5198301A (en) The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
WO2016130179A1 (en) Cenicriviroc for the treatment of fibrosis
KR101722432B1 (ko) 류마티스성 관절염 등 자가면역 질환 치료의 개선방법
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
CN107106566A (zh) 晶状体硬化抑制剂
HK1254388B (zh) 用於抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物
WO2005055997A1 (ja) 炎症性疾患の治療及び予防用医薬組成物
ES2363931T3 (es) Agente reparador para enfermedad glumerular.
EP1973943A1 (en) New method for the treatment of gout or pseudogout
KR20140075362A (ko) 다폭세틴을 유효성분으로 포함하는 통증 치료용 약학 조성물

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements